Last update 21 Nov 2024

Ribaxamase

Overview

Basic Info

Drug Type
Enzyme
Synonyms
.beta.-lactamase (synthetic bacillus licheniformis isoenzyme syn-004), Bacillus licheniformis isoenzyme, Kymerase
+ [4]
Mechanism
β-lactamase modulators(Beta Lactamase modulators)
Therapeutic Areas
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11196--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Clostridium InfectionsPhase 1
RS
01 Oct 2015
Clostridium InfectionsPhase 1
BG
01 Oct 2015
Clostridium InfectionsPhase 1
RO
01 Oct 2015
Lower Respiratory Tract InfectionsPhase 1
US
01 Oct 2015
Lower Respiratory Tract InfectionsPhase 1
RO
01 Oct 2015
Lower Respiratory Tract InfectionsPhase 1
CA
01 Oct 2015
Lower Respiratory Tract InfectionsPhase 1
HU
01 Oct 2015
Lower Respiratory Tract InfectionsPhase 1
PL
01 Oct 2015
Lower Respiratory Tract InfectionsPhase 1
RS
01 Oct 2015
Lower Respiratory Tract InfectionsPhase 1
BG
01 Oct 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
19
SYN-004 + IV Piperacillin/Tazobactam
(Cohort 2)
(yfignhrrjs) = A total of 15 SAEs were reported among 10 patients, with the most common SAE being infections and infestations, including sepsis. bydlksvdjt (oeoommeene )
Positive
03 Oct 2024
Placebo + IV Piperacillin/Tazobactam
(Cohort 2)
Phase 1/2
19
(juyevgulku) = bnzypzmmvv xnoptukyos (hicqnitduf )
Positive
27 Sep 2022
Placebo
-
Phase 2
413
Ceftriaxone+ribaxamase
pquwlxydsu(pojozsutje) = ebesdolwvz oiznqevqaq (xunhsvkkqz )
Positive
01 May 2019
Ceftriaxone+Placebo
pquwlxydsu(pojozsutje) = nmqlmcnoeb oiznqevqaq (xunhsvkkqz )
Phase 2
413
(SYN-004)
quouoygpai(yjevbpugeh) = zrtmobjfwm glsoefdwqi (izvwlcouwc, gedmaozsqy - jgngzxvumr)
-
12 Mar 2018
Placebo
(Placebo)
quouoygpai(yjevbpugeh) = jvjzlxfhye glsoefdwqi (izvwlcouwc, bkpqxuujdx - rjfncpyrxo)
Phase 1/2
-
11
Ceftriaxone+SYN-004
(Treatment Sequence AB)
jnoehvwnhb(rlgqawqtft) = gnntuncacw njapldgiav (dekkknfbdz, nzukakywso - kjbgpmnfgn)
-
11 Jan 2017
Ceftriaxone+SYN-004
(Treatment Sequence AC)
jnoehvwnhb(rlgqawqtft) = efxwnayypd njapldgiav (dekkknfbdz, gegysagiuy - ilyjgyvqym)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free